AAV formulation development: Extend serotype characterization with OMNISEC

Log in to watch this webinar

Not registered yet? Konto erstellen

Developing controlled and economical rAAV therapies requires robust and reliable characterization tools to control and optimize a sample’s critical quality attributes (CQAs).

Join this webinar as Malvern Panalytical experts demonstrate how you can use OMNISEC to extend characterization of multiple AAV serotypes. 

You’ll learn how this technique helps you measure critical parameters that impact the final product’s CQAs:

• evaluate and compare viral titer

• assess capsid empty/full ratios

• assess impurity and aggregate profiling

See how OMNISEC streamlines analysis by eliminating the need for costly reference standards that limit the application of other methodologies.

Register now to see how you can push the limits of rAAV analysis with OMNISEC.


Mallory Pearce - Lab Application Specialist Malvern Panalytical

Weitere Informationen

- Who should attend?

Scientists working in pharmaceutical and biologic analytical development, formulation and stability assessment.

Those working with viral vector development, gene therapies and associated sample types.

- What will you learn?

Learn how the latest advances in OMNISEC can deliver CQAs for rAAV development

See how this standard-free analysis can work for a range of serotypes

Learn how multi-parameter characterization of rAAV samples can be achieved in one sample run